NasdaqGS:BEAMBiotechs
A Look At Beam Therapeutics (BEAM) Valuation After Updated BEAM 302 Trial Data And Accelerated Approval Plans
Why BEAM-302’s latest data matters for Beam Therapeutics stock
Beam Therapeutics (BEAM) has drawn fresh attention after presenting updated Phase 1/2 BEAM-302 data for alpha-1 antitrypsin deficiency at the ATS 2026 conference, highlighting safety outcomes, durability signals and reduced neutrophil elastase activity.
See our latest analysis for Beam Therapeutics.
The updated BEAM-302 data has arrived alongside strong momentum in the stock, with a 7 day share price return of 14.98% and a year to...